A federal judge refused AstraZeneca’s request to temporarily ban companies from selling generic versions of rosuvastatin calcium (Crestor), Bloomberg reports. Barring an appeal, companies will be able to sell cheaper versions of the blockbuster medication, which accounted for more than $5 billion in sales.
On May 31, AstraZeneca filed an appeal asking the FDA for extended patent exclusivity for the drug, which is used to lower blood cholesterol. If the appeal fails, Bloomberg projects sales of rosuvastatin calcium would decrease to $3.5 billion this year.
Read the full article below: